The FDA approved a gene therapy for hemophilia — the latest in a series of decisions to advance pricey, personalized treatments that bring new hope to patients, along with cost concerns to the health system.
The Food and Drug Administration on Tuesday approved a gene therapy for hemophilia — the latest in a series of decisions to advance pricey, personalized treatments that bring new hope to patients, along with cost concerns to the health system.With a list price of $3.5 million, Hemgenix from CSL Behring LLC will become the most expensive therapy in the world.
The treatment is given as a single dose by IV and contains a viral vector carrying a gene for the clotting factor. Its effectiveness was established based on decreases in the annualized bleeding rate of subjects in two studies. “Gene therapy for hemophilia has been on the horizon for more than two decades," said Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research, adding Tuesday's decision "represents important progress in the development of innovative therapies for those experiencing a high burden of disease associated with this form of hemophilia.”
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FDA Approves First Drug to Delay Onset of Type 1 Diabetes - MedicineNet Health NewsThe U.S. Food and Drug Administration on Thursday approved the first drug that could delay the development of type 1 diabetes (T1D).
Read more »
FDA approves the first-ever drug that can delay the progression of Type 1 diabetesThe drug is an intravenous infusion that can postpone the onset of diabetes in patients.
Read more »
FDA Approves First Drug to Delay Progression of Type 1 DiabetesThe FDA approved the new diabetes treatment Tzield, an injectable treatment that can slow the progression of Type 1 diabetes in patients with stage 2 and delay the need for injectable insulin by two years.
Read more »
FDA Alert: 'Substantial' Hypocalcemia Risk with Prolia UseThe US Food and Drug Administration sent an alert today that it's investigating an apparent link between the use of denosumab (Prolia) by patients on dialysis and serious hypocalcemia outcomes.
Read more »
Why the FDA Is Asking Parents to Stop Using Neck FloatsNeck floats, designed to support a baby's head while their body floats, may seem like a fun idea but are dangerous to use. Learn why the CPSC is cautioning parents against the devices.
Read more »
$3.5M gene therapy for hemophilia gets FDA approvalU.S. health regulators on Tuesday approved the first gene therapy for hemophilia, a $3.5 million one-time treatment for the blood-clotting disorder. The Food and Drug Administration cleared Hemgenix, an IV treatment for adults with hemophilia B, the less common form of the genetic disorder which primarily affects men. Drugmaker CSL Behring announced the $3.5 million price tag shortly after the FDA approval, saying its drug would ultimately reduce health care costs because patients would have fewer bleeding incidents and need fewer clotting treatments.
Read more »